News & AnalysisAgomAb Therapeutics garners $74m Series BDrug developer AgomAb Therapeutics has secured $74 million in Series B financing.ByIris Dorbian10 March 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs